Discover and read the best of Twitter Threads about #immunoglobulin
Most recents (5)
✨ We're delighted to present a new Special Issue on Human #Bcells!
Guest edited by @BemarkMats, @JoSpencerLab & @Thomas_J_Tull, this collection explores the complexity of #Bcell development & function
Explore the articles below 🧵 & read for free ➡️bit.ly/40O6Onh
1/10
Guest edited by @BemarkMats, @JoSpencerLab & @Thomas_J_Tull, this collection explores the complexity of #Bcell development & function
Explore the articles below 🧵 & read for free ➡️bit.ly/40O6Onh
1/10
As well as #Bcell subtypes in health & inflammatory diseases, this collection also examines aspects of B cell diversity depending on #immunoglobulin isotype & in a microanatomical context
Our guest editors introduce the series in this Editorial 👇 2/10
academic.oup.com/cei/article/21…
Our guest editors introduce the series in this Editorial 👇 2/10
academic.oup.com/cei/article/21…
Rebekah Velounias & @Thomas_J_Tull @KCLImmunoMicro kick off the series papers with a discussion of B cell subset classification & their changes in #inflammatory disease 3/10
academic.oup.com/cei/article/21…
academic.oup.com/cei/article/21…
🧵 *** The researchers found no evidence of a difference in response in biochemical markers of #inflammation between patients with #MIS-C/PIMS-TS who were treated with #IVIG, #steroids, or #biologics, compared with those who were not.
*** Despite a lack of evidence, 🇬🇧 and 🇺🇸 treatment guidelines for MIS-C/PIMS-TS have become very similar.
*** By the end of the study period, most patients had received immunomodulation.
#AcademicChatter #AcademicTwitter #MedTwitter #foamed #MedStudentTwitter #LongCovidKids
*** By the end of the study period, most patients had received immunomodulation.
#AcademicChatter #AcademicTwitter #MedTwitter #foamed #MedStudentTwitter #LongCovidKids
#Plasma from recovered #COVID19 patients with high levels of #antibodies appeared to delay / stop progression of illness in mildly ill older adults infected with #SARSCoV2, a study published in @NEJM concluded. 🧵nejm.org/doi/full/10.10…
Researchers at Fundacion INFANT in Buenos Aires, #Argentina, led the small randomized, controlled, double-blind #clinicaltrial of the effects of infusing #convalescent #plasma in 160 older adults within 72 hours of symptom onset, half of whom received the treatment.
The patients were either 75 years and older with or without underlying illnesses, or 65 to 74 years with at least one underlying condition. The trial was stopped early because #COVID19 cases substantially declined in #BuenosAires, precluding continued recruitment.
"The live SARS-like coronavirus SL-CoV-WIV1 has been isolated for the first time from bat droppings; and such virus has been confirmed to invade the host cells through the ACE2 of human beings..."
Bat Severe Acute Respiratory Syndrome-Like Coronavirus WIV1
Encodes an Extra Accessory Protein, ORFX, Involved in Modulation of the Host Immune Response. (2016) #ZhengLiShi #PeterDaszak #EcoHealth
Funding: #NIAID 110964
Encodes an Extra Accessory Protein, ORFX, Involved in Modulation of the Host Immune Response. (2016) #ZhengLiShi #PeterDaszak #EcoHealth
Funding: #NIAID 110964
In this study, we have developed a fast and cost-effective method
for reverse genetics of coronaviruses by combining two approaches developed by others..As the genomes can be divided into multiple short fragments, mutations can be introduced into individual
fragments easily.
for reverse genetics of coronaviruses by combining two approaches developed by others..As the genomes can be divided into multiple short fragments, mutations can be introduced into individual
fragments easily.
What evidence has the @JHSPH_NCRC reviewed to date on treatments for COVID-19? 💊💉🩸
From Gautret et al. in International Journal of Antimicrobial Agents:
Viral shedding appeared lower in the #hydroxychloroquine arm; however, important differences between groups may also explain the effect seen. bit.ly/2W5meov
Viral shedding appeared lower in the #hydroxychloroquine arm; however, important differences between groups may also explain the effect seen. bit.ly/2W5meov
From Gautret et al. in International Journal of Antimicrobial Agents:
The study did not formally assess clinical endpoints, and it is unclear whether there is #COVID19 clinical benefit with #hydroxychloroquine treatment. bit.ly/2W5meov
The study did not formally assess clinical endpoints, and it is unclear whether there is #COVID19 clinical benefit with #hydroxychloroquine treatment. bit.ly/2W5meov
